Bioxytran (BIXT) Other financing activities (2010 - 2026)

Bioxytran (BIXT) posted Other financing activities of $95339.0 for Q1 2026, up 61.59% sequentially from $59000.0 in Q2 2024.

Bioxytran (BIXT) Other financing activities (2010 - 2026) Analysis & Trends

Bioxytran has reported Other financing activities for 12 years, with the latest figure at $95339.0 in Q1 2026.

Quarterly Other financing activities changed N/A year-over-year to $95339.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $154339.0 (changed N/A YoY) and the FY2025 annual result came in at $292230.0, up 363.86% from the prior year.
Other financing activities advanced to $95339.0 in Q1 2026 per BIXT's latest filing, from $59000.0 in the prior quarter.
Over five years, Other financing activities peaked at $557750.0 in Q3 2022 and troughed at $4000.0 in Q1 2024.
A 4-year average of $180593.0 and a median of $78000.0 in 2022 frame the typical range for Other financing activities.
The sharpest annual moves came in 2023 and 2024: Other financing activities advanced 18.34% in 2023, then slumped 92.0% in 2024.
Over 4 years, Other financing activities stood at $78000.0 in 2022, then surged by 400.46% to $390361.0 in 2023, then sank by 84.89% to $59000.0 in 2024, then jumped by 61.59% to $95339.0 in 2026.
According to Business Quant data, Other financing activities over the past three periods registered $95339.0, $59000.0, and $4000.0 for Q1 2026, Q2 2024, and Q1 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Bioxytran	2.47 Mn	2.22 Mn	-

Download Data